Cencora — Feb 5, 2025 release

Additionally, the Company is updating its fiscal year 2025 financial guidance expectations for revenue, operating income and net interest expense to reflect the impact of the RCA acquisition and the continued momentum in the U.S. Healthcare Solutions segment. The Company now expects: • Revenue growth to be in the range of 8 to 10 percent, from the previous range of 7 to 9 percent; ◦ U.S. Healthcare Solutions revenue growth to be in the range of 9 to 11 percent, from the previous range of 7 to 9 percent; ◦ International Healthcare Solutions revenue growth to be in the range of 4 to 5 percent, from the previous range of 7 to 9 percent; • Adjusted diluted EPS to be in the range of $15.25 to $15.55, up from the previous range of $15.15 to $15.45 provided on January 2, 2025 and the initial guidance range of $14.80 to $15.10. Additional expectations now include: • Adjusted consolidated operating income growth to be in the range of 11.5 to 13.5 percent, from the previous range of 5 to 6.5 percent; ◦ U.S. Healthcare Solutions segment operating income growth to be in the range of 14.5 to 16.5 percent, from the previous range of 5 to 6.5 percent; ◦ International Healthcare Solutions segment as reported operating income growth to be flat, from the previous range of 5 to 6.5 percent; ▪ On a constant currency basis, International Healthcare Solutions segment operating income growth to be approximately 5 percent; • Net interest expense to be in the range of $290 million to $310 million, from the previous range of $150 million t